Usual dose treatment of Tandospirone + Comparative high dose of tandospirone treatment

ApprovedCompleted

2 views this week 0 watching⚡ Active

Interest: 43/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Generalized Anxiety Disorder

Conditions

Generalized Anxiety Disorder

Trial Timeline

Jan 10, 2012 → Jul 1, 2019

NCT ID

NCT01614041

About Usual dose treatment of Tandospirone + Comparative high dose of tandospirone treatment

Usual dose treatment of Tandospirone + Comparative high dose of tandospirone treatment is a approved stage product being developed by Sumitomo Pharma for Generalized Anxiety Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT01614041. Target conditions include Generalized Anxiety Disorder.

What happened to similar drugs?

11 of 20 similar drugs in Generalized Anxiety Disorder were approved

Approved (11) Terminated (3) Active (8)

✅Duloxetine + PlaceboEli LillyApproved

✅IxekizumabEli LillyApproved

✅EscitalopramAbbVieApproved

✅QuetiapineAstraZenecaApproved

✅Alprazolam (Xanax) + PlaceboRocheApproved

✅Ziprasidone + PlaceboPfizerApproved

✅Pregabalin + Lorazepam + Pregabalin + PlaceboPfizerApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01614041	Approved	Completed	Jan 10, 2012	Jul 1, 2019	Generalized Anxiety Disorder

Competing Products

20 competing products in Generalized Anxiety Disorder

See all competitors

Product	Company	Stage	Hype Score
atomoxetine + placebo	Eli Lilly	Phase 2/3	38
Satralizumab	Chugai Pharmaceutical	Phase 3	32
Perampanel	Eisai	Pre-clinical	26
Perampanel + Placebo comparator	Eisai	Phase 3	40
zonisamide	Eisai	Pre-clinical	26
Fycompa	Eisai	Pre-clinical	26
Fycompa	Eisai	Pre-clinical	26
Perampanel	Eisai	Phase 3	40
Perampanel	Eisai	Pre-clinical	26
Cenobamate	Ono Pharmaceutical	Phase 3	47
Duloxetine + Placebo	Eli Lilly	Phase 3	40
Duloxetine + Placebo	Eli Lilly	Approved	43
Ixekizumab	Eli Lilly	Approved	43
eszopiclone + eszopiclone + Placebo	Sumitomo Pharma	Phase 2	35
ABBV-932 + Placebo for ABBV-932 + Antidepressant Therapy (ADT)	AbbVie	Phase 2	42
Cariprazine 0.75 mg/day + Cariprazine 1.5 mg/day + Cariprazine 3.0 mg/day	AbbVie	Phase 2	27
ABBV-932 + Placebo	AbbVie	Phase 1	29
Escitalopram	AbbVie	Approved	43
Adalimumab	AbbVie	Phase 3	40
Quetiapine fumarate + Paroxetine	AstraZeneca	Phase 3	40